期刊文献+

索格列净

Sotagliflozin(Inpefa)
原文传递
导出
摘要 索格列净(sotagliflozin)是由Lexicon Pharmaceuticals公司研发的一种可口服的钠依赖性葡萄糖协同转运蛋白(sodium-dependent glucose transporter,SGLT)抑制剂,于2023年5月26日经美国FDA批准上市,商品名为Inpefa。索格列净可降低2型糖尿病、慢性肾脏疾病和其他心血管危险因素所导致的心血管死亡或心力衰竭的风险[1]。索格列净的中文化学名称:(2S,3R,4R,5S,6R)-2-[4-氯-3-(4-乙氧基苄基)苯基]-6-(甲硫基)四氢-2H-吡喃-3,4,5-三醇;英文化学名称:(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl) phenyl]-6-(methylthio) tetrahydro-2H-pyran-3,4,5-triol;分子式:C21H25ClO5S;分子量:424.94;CAS登记号:1018899-04-1。
机构地区 沈阳药科大学
出处 《中国药物化学杂志》 CAS 2023年第12期966-966,共1页 Chinese Journal of Medicinal Chemistry
  • 相关文献

参考文献4

二级参考文献55

  • 1Danaei G~ Finucane M M, Lu Y, et al. National, regional, and global trends in fasting plasma glugose and diabetes prevanlence since 1980: systematic analysis of health examination surveys and epidemiologieal studies with 370 country-years and 2.7 million participants [J]. Lancet, 2011, 378(9785): 31-40.
  • 2Dietrich E, Powell J, Taylor J R. Canagliflozin: a novel treatment option for type 2 diabetes [J]. Drug Des Deve! Ther, 2013, 22(7): 1399-1408.
  • 3Rosebraugh C J. Dapagliflozin new drug application approval letter [OL]. [2014-09-05]. http://www.accessdata. fda.gov/drugsat fda__docs/appletter/2014/202293Orig 1 s0001tr. pdf.
  • 4Rosebraugh C J. Empagliflozin new drug application approval letter [OL]. [2014-09-05]. http://www, access data. fda. gov/drugsat fda docs/appletter/2014/204629Orig I s 0001tr.pdf.
  • 5Wright E M, Loo D D F, Hriayama B A. Biology of human sodium glucose transporters [J]. Physiol Rev, 2011, 91: 733-794.
  • 6Zambrowicz B, Freiman J, Brown P M, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial [J]. Clin Pharmacol Ther, 2012, 92(2): 158-169.
  • 7Powell D R, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporterl (SGLT1)- mediated absorption of intestinal glucose [J]. J Pharmacol Exp Ther, 2013, 345(2): 250-259.
  • 8Powell D R, DaCosta C M, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models [J]. J Pharmacol Exp Ther, 2014, 350(2): 232-242.
  • 9Freiman J, Ye C~ Ogbaa I, et al. A phase 1, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study to determine the safety and tolerability of orally administered LX4211 in healthy human subjects [R]. Woodlands: Clinical Study Report LX4211.101, 2010.
  • 10Freiman J, Ye G, Ogbaa I. LX4211, a dual SGLT1/SGLT2 inhibitor shows a favorable gastrointestinal and genitourinary safety profile in type 2 diabetes mellitus (T2DM) patients and healthy subjects [C]. Berlin: 48th EASD AnnualMeeting, 2012.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部